Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Good Risk0–0
- Intermediate Risk1–2
- High Risk3–5
The Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC) calculator is designed for bedside predicting survival based on clinical and laboratory data in metastatic RCC patients in clinical practice. The resulting score directly guides clinician decision-making regarding adjusting systemic antineoplastic regimens.
Clinical Guidelines & Evidence
Predicts survival based on clinical and laboratory data in metastatic RCC patients
Clinical Indication
The Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC) is indicated for bedside clinical practice to support Predicts survival based on clinical and laboratory data in metastatic RCC patients. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
Score = Sum of present risk factors (0-5)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| time_to_treatment_less_than_1_year | string | Yes | Time from initial diagnosis to systemic treatment < 1 year |
| hemoglobin_low | string | Yes | Hemoglobin < lower limit of normal (Men: <13.5 g/dL, Women: <12.0 g/dL) |
| calcium_high | string | Yes | Corrected calcium > 10 mg/dL (>2.5 mmol/L) |
| ldh_high | string | Yes | LDH > 1.5x upper limit of normal (Normal ULN: 140 U/L, so >210 U/L) |
| performance_status_low | string | Yes | Karnofsky Performance Status < 80% |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Good Risk | 0 risk factors |
| 1–2 | Intermediate Risk | 1-2 risk factors |
| 3–5 | High Risk | ≥3 risk factors |
Evidence-Based References (EBM)
- Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 Aug;17(8):2530-40. doi: 10.1200/JCO.1999.17.8.2530.DOI: 10.1200/JCO.1999.17.8.2530
- Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 Jan 1;20(1):289-96. doi: 10.1200/JCO.2002.20.1.289.DOI: 10.1200/JCO.2002.20.1.289
- Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004 Feb 1;22(3):454-63. doi: 10.1200/JCO.2004.06.132.DOI: 10.1200/JCO.2004.06.132
Related calculators
- Mekhail Extension of the Motzer Score
- Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)
- Khorana Risk Score for Venous Thromboembolism in Cancer Patients
- Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes
- Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) Score